Evidence map›Paper›PMID 37407914›Full record

ArticleBMC neurology2023

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.

Stefan Braune, Sandra Bluemich, Carola Bruns, Petra Dirks, Jeanette Hoffmann, Yanic Heer, Erwan Muros-Le Rouzic, Arnfin Bergmann, NTD Study Group

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Barriers to clinical follow-up visits in multiple sclerosis: A nationwide register-based study.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Stefan BrauneNeuroTransData, Neuburg an der Donau, Germany. sbraune@neurotransdata.com.
Sandra BluemichRoche Pharma AG, Grenzach-Wyhlen, Germany.
Carola BrunsRoche Pharma AG, Grenzach-Wyhlen, Germany.
Petra DirksF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Jeanette HoffmannRoche Pharma AG, Grenzach-Wyhlen, Germany.
Yanic HeerPricewaterhouseCoopers (PwC), Zurich, Switzerland.
Erwan Muros-Le RouzicF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Arnfin BergmannNeuroTransData, Neuburg an der Donau, Germany.
NTD Study Group
Roche Pharma AG (Germany) · DEKlinik Donaustauf · DERoche (Switzerland) · CHMetrogiprotrans (Russia) · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary progressive multiple sclerosis (PPMS) is characterised by gradual worsening of disability from symptom onset. Knowledge about the natural course of PPMS remains limited.

methodsPPMS patients from the German NeuroTransData (NTD) MS registry with data from 56 outpatient practices were employed for retrospective cross-sectional and longitudinal analyses. The cross-sectional analysis included a contemporary PPMS cohort with a documented visit within the last 2 years before index date (1 Jan 2021). The longitudinal analysis included a disease modifying therapy (DMT)-naïve population and focused on the evolution of expanded disability status scale (EDSS) from the first available assessment at or after diagnosis within the NTD registry to index date. Outcome measures were estimated median time from first EDSS assessment to first 24-week confirmed EDSS ≥ 4 and ≥ 7. Besides EDSS change, the proportion of patients on disability pension were described over time.

resultsThe cross-sectional analysis included 481 PPMS patients (59.9% female, mean [standard deviation, SD] age 60.5 [11.5] years, mean [SD] EDSS 4.9 [2.1]). Estimated median time from first EDSS assessment after diagnosis to reach 24-week confirmed EDSS ≥ 4 for DMT-naïve patients was 6.9 years. Median time to EDSS ≥ 7 was 9.7 years for 25% of the population. Over a decade mean (SD) EDSS scores increased from 4.6 (2.1) to 5.7 (2.0); the proportion of patients on disability pension increased from 18.9% to 33.3%.

conclusionsThis study provides first insights into the German NTD real-world cohort of PPMS patients. Findings confirm the steadily deteriorating course of PPMS accompanied by increasingly limited quality of life.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveCross-Sectional StudiesDisease ProgressionFemaleHumansMaleMiddle AgedQuality of LifeRegistriesRetrospective StudiesCohort studiesNatural historyPrimary progressive multiple sclerosisQuality of lifeRetrospective study

Identifiers

PMID37407914
PMCPMC10320981
OpenAlexW4383263331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.